The 4.3% decline in antibiotic prescriptions is the first time a reduction in antibiotic use has been seen across the whole healthcare system, the 'English Surveillance Programme for Antimicrobial Utilisation and Resistance’ (ESPAUR) report, said.
Inappropriate use of antibiotics, such a taking them for viruses like colds and flu, fuels resistance and experts have warned for some diseases there are no effective medicines left.
Professor Gillian Leng, deputy chief executive at NICE said: “This new data published by PHE shows that our attitudes are changing for the better. Now we must work hard to maintain this momentum.”
Antibiotic resistance is one of the greatest dangers to our health. Dame Sally Davies, the UK Chief Medical Officer, has described the threat as “catastrophic”. It could lead to people dying from ordinary infections, and routine operations such as hip replacements becoming deadly due to the risk of infection.
By safely reducing the number of antibiotics prescribed inappropriately we can combat antibiotic resistance. NICE is currently seeking comments on proposed ‘management of common infections’ guidelines. This suite of guidance will provide evidence-based advice on how common infections can be managed, with the purpose of tackling antibiotic resistance.
“Establishing better ways of using our current antibiotics is vital, and this will be informed by new NICE guidance on managing common infections”, Professor Leng added. "Our guidance on the prescribing of antibiotics for respiratory tract infections, an area where antibiotics are often over prescribed, is an example of this advice already in action. And our ‘antimicrobial stewardship’ guidance lays out how to protect the antibiotics we currently have. We will also be producing prescribing summaries for all new antimicrobials, with advice on how they should be used in practice”, Professor Leng added. This will require close links to the PHE resistance data, to ensure new antimicrobials are used only when necessary. New NICE advice will help protect new antimicrobials for future generations.”